Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery, Silicos Ink Screening Pact

NEW YORK (GenomeWeb News) – Horizon Discovery has signed a commercial agreement with the drug discovery company Silicos for testing compounds on human isogenic cell lines based on specific genotypes, Horizon said on its website Monday.

The agreement covers the testing of Silicos compounds using Horizon's X-MAN mutant and normal cell line technology to enable the drug maker to gather information about its compounds, including data about selectivity and mode-of-action, using model in vitro systems. Such genotype-specific compound studies could help pharmaceutical and biotech companies advance their aims in personalized medicine, Horizon said.

Horizon Chairman Darrin Disley said in a statement that Silicos' multi-target screening approach is "should lead to the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases including cancer."

Financial terms of the agreement were not released.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.